Gefitinib CAS 184475-35-2 Ịdị ọcha> 99.5% (HPLC)
Shanghai Ruifu Chemical Co., Ltd bụ onye na-emepụta ihe na-emepụta Gefitinib (CAS: 184475-35-2) nwere àgwà dị elu.Ruifu Chemical nwere ike ịnye nnyefe zuru ụwa ọnụ, ọnụahịa asọmpi, ọrụ magburu onwe ya, obere na nnukwu ọnụọgụ dị.Ịzụta Gefitinib na ndị etiti,Please contact: alvin@ruifuchem.com
| Aha Chemical | Gefitinib |
| Ụdị okwu | Gefitinib Free base;Iressa;ZD1839;ZD-1839;N- (3-Chloro-4-Fluorophenyl) -7-Methoxy-6- (3-Morpholinopropoxy) quinazolin-4-Amine;N- (3-Chloro-4-Fluorophenyl) -7-Methoxy-6-[3- (4-Morpholinyl) propoxy]-4-Quinazolinamine |
| Ọnọdụ Ahịa | Na ngwaahịa, Mmepụta Azụmahịa |
| Nọmba CAS | 184475-35-2 |
| Usoro ihe omimi | C22H24ClFN4O3 |
| Ibu molekụla | 446.91 g/mol |
| Ebe Na-agbaze | 194.0 ruo 198.0 ℃ |
| Njupụta | 1.322±0.06 g/cm3 |
| Mmiri Solubility | Na-adịghị edozi n'ime mmiri |
| Solubility | Soluble na DMSO |
| Okpomọkụ nchekwa. | Okpomọkụ ụlọ |
| Mbupu | Ambient |
| COA & MSDS | Dị |
| Mmalite | Shanghai, China |
| Ụdị | Ruifu Chemical |
| Ihe | Ụkpụrụ nyocha | Nsonaazụ |
| Ọdịdị | Ọcha ka Gbanyụọ-Ọcha ntụ ntụ | Na-akwado |
| Ọnwụ na ihicha | <0.50% | 0.13% |
| Ihe fọdụrụ na mgbanye | <0.20% | 0.06% |
| Otu adịghị ọcha | <0.10% | 0.09% |
| Mgbakọta adịghị ọcha | <0.50% | 0.20% |
| Ọla dị arọ (Pb) | ≤10ppm | <10ppm |
| Ụzọ ịdị ọcha / nyocha | > 99.5% (HPLC) | 99.80% |
| Spectrum infrared | Nkwekọ na Structure | Na-akwado |
| 1H NMR Spectrum | Nkwekọ na Structure | Na-akwado |
| Mmechi | A nwalela ngwaahịa a wee kwado nkọwa ndị enyere | |
ngwugwu:Fluorinated Bottle, Aluminom foil bag, 25kg / Cardboard Drum, ma ọ bụ dị ka ndị ahịa chọrọ.
Ọnọdụ Nchekwa:Debe akpa ahụ nke ọma ma debe ya n'ụlọ nkwakọba ihe dị jụụ, kpọrọ nkụ na nke ikuku na-ekpo ọkụ n'ebe ihe na-adabaghị adaba.Chebe site na ìhè na mmiri mmiri.
Mbupu:Jiri ikuku na-ebuga ụwa niile site na FedEx / DHL Express.Nye nnyefe ngwa ngwa na ntụkwasị obi.
Ọ bụghị maka iji na mmadụ.Ọ bụghị maka ojiji na diagnostics ma ọ bụ therapeutics.Maka nyocha in vitro, jiri naanị ya.
Ọ nweghị ngwaahịa ọ bụla a ga-enye na mba ndị nke a nwere ike megidere ikike ikike dị ugbu a.Agbanyeghị, ọrụ ikpeazụ dị n'aka onye zụrụ ya.
Kedu ka esi azụta?Biko kpọtụrụDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
Ahụmịhe afọ 15?Anyị nwere ihe karịrị 15 afọ nke ahụmahụ na mmepụta na mbupụ nke a dịgasị iche iche nke elu mma pharmaceutical intermediates ma ọ bụ ezi kemịkal.
Isi ahịa?Na-ere ahịa ụlọ, North America, Europe, India, Korea, Japanese, Australia, wdg.
Uru?Ogo kachasị elu, ọnụ ahịa dị ọnụ ala, ọrụ ọkachamara na nkwado teknụzụ, nnyefe ngwa ngwa.
OgoNkwenye?Usoro njikwa mma siri ike.Ngwá ọrụ ọkachamara maka nyocha gụnyere NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, wdg.
Ihe atụ?Ọtụtụ ngwaahịa na-enye ihe nlele efu maka nyocha dị mma, ndị ahịa kwesịrị ịkwụ ụgwọ mbupu.
Nyocha ụlọ ọrụ?Nnabata nyocha ụlọ ọrụ.Biko mee oge oge tupu oge eruo.
MOQ?Enweghị MOQ.A na-anabata obere usoro.
Oge Mbuga ozi? Ọ bụrụ n'ime ngwaahịa, ekwenyere nnyefe ụbọchị atọ.
Ụgbọ njem?Site Express (FedEx, DHL), nke ikuku, site n'oké osimiri.
Akwụkwọ?Mgbe ọrụ ahịa gasịrị: COA, MOA, ROS, MSDS, wdg nwere ike ịnye.
Synthesis omenala?Nwere ike ịnye ọrụ nhazi ahaziri iche ka ọ dabara mkpa nyocha gị nke ọma.
Usoro ịkwụ ụgwọ?A ga-ebu ụzọ ziga akwụkwọ ọnụahịa Proforma mgbe nkwenye nke iwu, kpuchiri ozi ụlọ akụ anyị.Ịkwụ ụgwọ site na T/T (Telex Nyefee), PayPal, Western Union, wdg.
| Nkọwapụta nchekwa | 24/25 - Zere kọntaktị na akpụkpọ ahụ na anya. |
| Koodu HS | 293499099 |
Gefitinib (CAS: 184475-35-2) bụ ọgwụ ọgwụgwọ ezubere iche maka mgbochi tumor nke AstraZeneca, UK mepụtara.Ọ bụ ọgwụ mbụ ezubere iche maka molekul maka ọgwụgwọ ọrịa kansa akpa ume na-abụghị obere cell.Ọ na-arụ ọrụ site n'ịhọrọ igbochi ụzọ ntụgharị mgbaàmà nke epidermal growth factor receptor tyrosine kinase (EGFR-TK).Epidermal growth factor (EGF) bụ a polypeptide na ikwu molekụla uka nke 6.45 × 103, nke nwere ike ijikọ na epidermal growth factor receptor (EGFR) na lekwasịrị cell akpụkpọ iji mepụta ndu mmetụta.EGFR bụ ụdị tyrosine kinase (TK).Mgbe ọ na-ejikọta na EGF, ọ nwere ike ịkwalite ọrụ TK n'ime ahụ onye na-enweta ya, na-eme ka autophosphorylation nke tyrosine residues na-anabata ya, na-enye akara ngosi nkewa na-aga n'ihu na sel, na-eme ka cell gbasaa na ọdịiche.EGFR dị ukwuu na anụ ahụ mmadụ ma na-egosipụta nke ọma na etuto ọjọọ.Site na igbochi ụzọ akara EGFR n'elu cell, gefitinib na-egbochi uto tumor, metastasis na angiogenesis, ma nwee ike ịkpata apoptosis nke mkpụrụ ndụ tumo.N'August 2002, a na-ere gefitinib na Japan dị ka ọgwụgwọ mbụ maka ọrịa cancer akpa ume na-abụghị obere cell n'okpuru aha ahia Iressa.Na May 2003, US Food and Drug Administration kwadoro gefitinib dị ka usoro ọgwụgwọ nke atọ maka ndị ọrịa nwere ọrịa cancer akpa ume na-abụghị obere cell bụ ndị na-adịghị arụ ọrụ na ọgwụ anticancer nke platinum dabeere na docetaxel chemotherapy.Ka ọ dị ugbu a, Australia, Japan, Argentina, Singapore na South Korea akwadola ya maka ọgwụgwọ ọrịa kansa akpa ume na-abụghị obere cell.Na February 28, 2005, ndị na-ahụ maka nri na ọgwụ ọjọọ nke China kwadoro gefitinib maka ọgwụgwọ nke ọrịa cancer akpa ume na mpaghara ma ọ bụ metastatic na-abụghị obere cell (NSCLC) nke natara na mbụ chemotherapy.A kwadobeghị ya ugbu a maka ojiji dị ka usoro ọgwụgwọ mbụ maka NSCLC dị elu.Na July 1, 2009, European Medicines Agency kwadoro gefitinib maka ọgwụgwọ nke mbụ, nke abụọ na ọgwụgwọ nke atọ nke ọrịa cancer akpa ume na mpaghara ma ọ bụ metastatic na-abụghị obere cell mutations na EGFR gene mutations na ndị okenye.
